Abstract
Interstitial lung disease is commonly associated with the autoimmune inflammatory myopathies dermatomyositis and polymyositis and accounts for significant morbidity and mortality in these conditions. In the 35 years since the association between inflammatory myopathy and interstitial lung disease was initially described, there has been progress in diagnosing and treating this dis-order. Nevertheless, there remains much about pathogenesis and therapeutics to be learned. This review examines the changes in the understanding of this complex condition, highlighting recent advances and areas deserving of further study.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Adrenal Cortex Hormones / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Azathioprine / therapeutic use
-
Biomarkers / blood
-
Biopsy, Needle
-
Bronchoscopy
-
Comorbidity
-
Cyclophosphamide / therapeutic use
-
Disease Progression
-
Drug Therapy, Combination
-
Female
-
Humans
-
Immunosuppressive Agents / therapeutic use*
-
Lung Diseases, Interstitial / diagnosis*
-
Lung Diseases, Interstitial / drug therapy
-
Lung Diseases, Interstitial / epidemiology*
-
Male
-
Methotrexate / therapeutic use
-
Myositis / diagnosis*
-
Myositis / drug therapy
-
Myositis / epidemiology*
-
Prognosis
-
Respiratory Function Tests
-
Risk Assessment
-
Severity of Illness Index
-
Survival Analysis
-
Time Factors
-
Tomography, X-Ray Computed
Substances
-
Adrenal Cortex Hormones
-
Biomarkers
-
Immunosuppressive Agents
-
Cyclophosphamide
-
Azathioprine
-
Methotrexate